158 related articles for article (PubMed ID: 7248987)
21. Phase II clinical trial of VP-16-213 in ovarian cancer.
Maskens AP; Armand JP; Lacave AJ; De Jager RL; Hansen HH; Wolff JP
Cancer Treat Rep; 1981; 65(3-4):329-30. PubMed ID: 7016320
[No Abstract] [Full Text] [Related]
22. Phase II study of etoposide for carcinoma of the bladder: the Southeastern Cancer Study Group experience.
Walther PJ; Williams SD; Troner M; Greco FA; Birch R; Einhorn LH
Cancer Treat Rep; 1986 Nov; 70(11):1337-8. PubMed ID: 3768877
[No Abstract] [Full Text] [Related]
23. Methotrexate treatment for advanced bladder cancer.
Hall RR; Bloom HJ; Freeman JE; Nawrocki A; Wallace DM
Br J Urol; 1974 Aug; 46(4):431-8. PubMed ID: 4414661
[No Abstract] [Full Text] [Related]
24. Combined chemotherapy and irradiation for transitional cell cancer of the bladder: a review.
Beuzeboc P; Pontvert D; Pouillart P; Cosset JM
J Infus Chemother; 1995; 5(4):218-20. PubMed ID: 8934733
[No Abstract] [Full Text] [Related]
25. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin as adjunctive treatment for invasive bladder carcinoma: tolerance and toxicities.
Einstein AB; Shipley W; Coombs J; Cummings KB; Soloway MS; Hawkins I
Urology; 1984 Apr; 23(4 Suppl):110-7. PubMed ID: 6538712
[No Abstract] [Full Text] [Related]
27. [Radiotherapy and chemotherapy in infiltrating bladder tumors].
Durdux C; Housset M
Rev Prat; 1997 Feb; 47(4):392-5. PubMed ID: 9114525
[TBL] [Abstract][Full Text] [Related]
28. Doxorubicin chemotherapy in advanced transitional cell carcinoma.
Weinstein SH; Schmidt JD
Urology; 1976 Oct; 8(4):336-41. PubMed ID: 973286
[TBL] [Abstract][Full Text] [Related]
29. [Long-term survival of bladder preservation therapy with radiation and chemotherapy for locally invasive bladder cancer].
Noguchi S; Takase K; Kubota Y; Masuda M; Yao M; Hosaka M
Hinyokika Kiyo; 1998 Mar; 44(3):149-53. PubMed ID: 9589874
[TBL] [Abstract][Full Text] [Related]
30. PHASE I clinical trial of an oral solution of VP-16-213.
Nissen NI; Dombernowsky P; Hansen HH; Larsen V
Cancer Treat Rep; 1976 Jul; 60(7):943-5. PubMed ID: 1009527
[No Abstract] [Full Text] [Related]
31. A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.
Cavalli F; Klepp O; Renard J; Röhrt M; Alberto P
Eur J Cancer (1965); 1981 Feb; 17(2):245-9. PubMed ID: 7262161
[No Abstract] [Full Text] [Related]
32. [Small cell carcinoma of the urinary bladder: a case report].
Yokoyama S; Tsutahara K; Fukuhara S; Mori N; Hara T; Yamaguchi S; Adachi S
Hinyokika Kiyo; 2005 Jun; 51(6):403-5. PubMed ID: 16050481
[TBL] [Abstract][Full Text] [Related]
33. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
[TBL] [Abstract][Full Text] [Related]
34. Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report.
DeFuria MD; Bracken RB; Johnson DE; Soloway MS; Merrin CE; Morgan LR; Miller HC; Crooke ST
Cancer Treat Rep; 1980; 64(2-3):225-30. PubMed ID: 7407754
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of the anticancer effect of cisplatin and etoposide against nude mice transplanted urological malignant tumors].
Gotoh A; Mizuno Y; Matsuwari S; Kitazawa S; Maeda S; Arakawa S; Kamidono S
Gan To Kagaku Ryoho; 1994 May; 21(6):899-902. PubMed ID: 8185353
[No Abstract] [Full Text] [Related]
36. The role of the nonsurgical oncologist in the management of advanced transitional cell cancer. Part I: locally advanced disease.
Mead GM; Roberts JT
BJU Int; 2004 Nov; 94(7):977-80. PubMed ID: 15541112
[No Abstract] [Full Text] [Related]
37. [Successful inhibition of bladder tumor recurrence by oral administration of UFT].
Nakamoto T; Igawa M; Usui T
Gan To Kagaku Ryoho; 1994 Apr; 21(5):697-9. PubMed ID: 8154896
[No Abstract] [Full Text] [Related]
38. Re: Agarwal a et al.: The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma (Urology 2007;70:1075-1078).
Agrawal MS; Bansal S
Urology; 2009 Feb; 73(2):450-1. PubMed ID: 19185768
[No Abstract] [Full Text] [Related]
39. Interview with Dr Richard Sylvester: transition cell carcinoma of the bladder. Interview by Christine McKillop.
Sylvester R
Eur Urol; 2007 Jun; 51(6):1748-50. PubMed ID: 17374436
[No Abstract] [Full Text] [Related]
40. Developing innovative strategies for advanced transitional cell carcinoma of the bladder.
Pollera CF; Nelli F
Expert Rev Anticancer Ther; 2006 Jan; 6(1):83-92. PubMed ID: 16375647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
